Moreover, recent studies further corroborate the feasibility and safety of LBBAP in patients with cardiac amyloidosis, emphasizing its potential as a viable pacing strategy for this complex patient population.4 The evidence from Patient 1, demonstrating improved electrical synchrony through LBBAP, as evidenced by reduced QRS duration and BNP levels, along with the absence of heart failure development over a 3-year follow-up, underscores the long-term benefits of LBBAP in managing cardiac amyloidosis with concomitant conduction disease. Here, NPPB is linked to heart failure.